David J Scott Net Worth

The estimated Net Worth of David J Scott is at least $43.9 Milion dollars as of 27 July 2012. David Scott owns over 143,500 units of AMGEN stock worth over $21,632,829 and over the last 21 years David sold AMGN stock worth over $22,276,215.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Scott AMGN stock SEC Form 4 insiders trading

David has made over 3 trades of the AMGEN stock since 2011, according to the Form 4 filled with the SEC. Most recently David sold 143,500 units of AMGN stock worth $12,006,645 on 27 July 2012.

The largest trade David's ever made was selling 143,500 units of AMGEN stock on 27 July 2012 worth over $12,006,645. On average, David trades about 6,319 units every 7 days since 2004. As of 27 July 2012 David still owns at least 65,558 units of AMGEN stock.

You can see the complete history of David Scott stock trades at the bottom of the page.

What's David Scott's mailing address?

David's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, CA, 91320-1799.

Insiders trading at AMGEN

Over the last 22 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer a Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.

What does AMGEN do?

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Complete history of David Scott stock trades at AMGEN

AMGEN executives and stock owners

AMGEN executives and other stock owners filed with the SEC include:

• Robert Bradway,
  Chairman of the Board, President, Chief Executive Officer
• Jonathan Graham,
  Senior Vice President, General Counsel, Secretary
• Murdo Gordon,
  Executive Vice President of Global Commercial Operations
• David Reese,
  Executive Vice President - Research and Development
• Robert A. Bradway,
  Chairman, CEO & Pres
• Murdo Gordon,
  Exec. VP of Global Commercial Operations
• Dr. David M. Reese M.D.,
  Exec. VP of R&D
• Esteban Santos,
  Exec. VP of Operations
• Peter H. Griffith,
  Exec. VP & CFO
• Robert Eckert,
  Lead Independent Director
• Gregory Garland,
  Independent Director
• Ronald Sugar,
  Independent Director
• Charles Holley,
  Independent Director
• Wanda Austin,
  Independent Director
• Brian Druker,
  Independent Director
• Fred Hassan,
  Independent Director
• Robert Williams,
  Independent Director
• Tyler Jacks,
  Independent Director
• Ellen Kullman,
  Independent Director
• Amy Miles,
  Independent Director
• Linda Louie,
  Vice President - Finance, Chief Accounting Officer
• David Piacquad,
  Senior Vice President - Business Development
• Lori Johnston,
  Senior Vice President - Human Resources
• Cynthia Patton,
  Senior Vice President, Chief Compliance Officer
• Esteban Santos,
  Executive Vice President, Operations
• Peter Griffith,
  Chief Financial Officer, Executive Vice President
• Nancy A. Grygiel,
  Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer
• Jonathan P. Graham,
  Exec. VP, Gen. Counsel & Sec.
• Arvind Sood,
  VP of Investor Relations
• Mike Zahigian,
  Sr. VP & Chief Information Officer
• Linda H. Louie,
  VP of Fin. & Chief Accounting Officer
• Annette Louise Such,
  CAO
• Frank Biondi,
  Director
• Greg C. Garland,
  Director
• Frank C Herringer,
  Director
• David W Meline,
  EVP & CFO
• Anthony C Hooper,
  EVP, Global Commercial Ops.
• R Sanders Williams,
  Director
• Rebecca M Henderson,
  Director
• Judith C Pelham,
  Director
• David Baltimore,
  Director
• Sean E Harper,
  EVP, Research & Development
• Carbonnel Francois De,
  Director
• James E. Bradner,
  EVP, R&D, & Chief Sci. Officer
• Nancy A. Grygiel,
  SVP & CCO
• Thomas James Flanagan,
  Sr VP & CIO
• Leonard D Schaeffer,
  Director
• Jonathan M Peacock,
  CFO
• Gilbert S Omenn,
  Director
• J Paul Reason,
  Director
• Thomas J.W. Dittrich,
  VP, Finance & CAO
• David J Scott,
  Sr. VP, Gen. Counsel & Secy.
• A Kelly Michael,
  VP Corp Plng & Control & CAO
• Stuart A Tross,
  SVP, Human Resources
• Kevin W Sharer,
  Chairman of the Bd, CEO & Pres
• Vance D Coffman,
  Director
• David W Beier,
  SVP Global Govt & Corp Affairs
• Fabrizio Bonanni,
  Senior VP, Manufacturing
• Anna Richo,
  SVP & CCO
• Jerry D Choate,
  Director
• Frederick W Gluck,
  Director
• Roger M Perlmutter,
  Exec VP Research & Development
• George J Morrow,
  Exe VP, Global Commercial Ops
• Brian M Mcnamee,
  Sr. V.P. Human Resources
• Richard D Nanula,
  Exe VP Fin, Strat & Comm & CFO
• Franklin P Jr Johnson,
  Director
• Donald B Rice,
  Director
• Dennis M Fenton,
  Executive Vice President
• Hassan Dayem,
  Sr. V.P. & Chief Info. Officer
• Barry D Schehr,
  VP Financial Ops & CAO
• Edward V Fritzky,
  Director
• Steven M Odre,
  Sr. VP, Gen. Cousel & Secy.
• Timothy O Martin,
  V.P., Planning and Control
• Beth C Seidenberg,
  Sr VP Development
• Willard H Dere,
  Sr. V.P., Global Dev & CMO
• Joseph P Miletich,
  Sr VP Rsch & Preclinical Dev
• Patricia C Sueltz,
  Director
• Steven Lazarus,
  Director
• Derek Miller,
  SVP, Human Resources
• Omar Ishrak,
  Director
• Rachna Khosla,
  SVP, Business Development
• Michael V Drake,
  Director
• Matthew C. Busch,
  VP, Finance & CAO
• Mary E. Klotman,
  Director